Optimised Fluoride Prevention by Double Rinse With Fluoride and Calcium
NCT ID: NCT01473537
Last Updated: 2012-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
9 participants
INTERVENTIONAL
2011-10-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Procedure: Rinses are performed in the evening. The rinse combinations are given in a random order, and the subjects are unaware of the sequence. At least 3 days separates the use of each rinse. Dosage: 20 mL and 1 minute rinse with each solution.
Saliva samples: Twelve hours after rinsing, unstimulated saliva samples are collected by expectoration.
Analysis: The fluoride concentration in saliva samples are analysed Statistics and data handling: Fluoride in saliva 12 hours after rinsing are examined by one-way ANOVA, repeated measures design.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Chewing a Calcium Supplement Before Fluoride Rinse on Salivary Fluoride
NCT04620252
Effect of Calcium Glycerophosphate (CaGP) - Fluoride Dentifrice on Dental Biofilm pH
NCT00875212
Intra Oral Kinetics of Fluoride Containing Dentifrices
NCT02548156
Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients
NCT01768390
Experimental Dentifrice Remineralization/Fluoride Uptake in an in Situ Model
NCT00752089
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
calcium lactate solution 75 mM
calcium lactate solution
Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
calcium lactate solution 150 mM
calcium lactate solution
Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
placebo
calcium lactate solution
Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
calcium lactate solution
Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 10 natural teeth or more
* willing to refrain from use of fluoride containing products
* signed informed consent
Exclusion Criteria
* reduced cognitive skills
* does not speak and/or understand Swedish
* ongoing oral or systemic infections
* pregnancy
* breast feeding
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska Institutet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gunilla Sandborgh Englund
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gunilla Sandborgh-Englund, Prof, DDS
Role: PRINCIPAL_INVESTIGATOR
Karolinska Institutet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska Institutet, Dept Dental Medicine
Huddinge, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-001885-16
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
DDM 2011/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.